Home › NDC Lookup › RxCUI directory › RxCUI 2686061

2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector — RxCUI 2686061

RxNorm drug concept · Semantic clinical drug
RxCUI 2686061 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2686061
Official name2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astralokinumab-ldrm 300 MG per 2 ML Auto-Injector; tralokinumab-ldrm 300 MG in 2 ML Auto-Injector
FDA products mapped2
Package NDCs mapped6
Reported Medicaid activity (SDUD)18,603 prescriptions · 37 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tralokinumab-ldrm injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Adbry is a biologic — a lab-made antibody that you inject under the skin. Unlike topical creams that work directly on the skin surface, Adbry travels through your bloodstream and b...
  • What exactly is Adbry and how is it different from my usual eczema creams?
  • For adults, you start with a loading dose and then inject every other week — or possibly every 4 weeks if your skin clears up well after 16 weeks and your weight is below 100 kg. T...
  • How often do I need to inject Adbry, and can I do it myself at home?
📖 Read our full Tralokinumab-ldrm injection guide →

🕸️ Concept Web — How 2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector RxCUI 2686061

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Tralokinumab 2589225
    • Tralokinumab-ldrm 2589374
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Adbry 2589380
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tralokinumab Auto-Injector 2686059
    • Tralokinumab-ldrm Auto-Injector 2686060
    • Tralokinumab Injectable Product 2589376
    • Tralokinumab-ldrm Injectable Product 2662034
    • Tralokinumab Auto-Injector [Adbry] 2686063
    • Tralokinumab-ldrm Auto-Injector [Adbry] 2686064
    • Adbry Injectable Product 2589382
    • Auto-Injector 1649570
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tralokinumab-ldrm 150 MG/ML SCDC · 2589375
  • Tralokinumab Auto-Injector SCDF · 2686059
  • Tralokinumab-ldrm Auto-Injector SCDFP · 2686060
  • Tralokinumab Injectable Product SCDG · 2589376
  • Tralokinumab-ldrm Injectable Product SCDGP · 2662034

Brand-Name Concepts

  • 2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector [Adbry] SBD · 2686065
  • Tralokinumab-ldrm 150 MG/ML [Adbry] SBDC · 2589381
  • Tralokinumab Auto-Injector [Adbry] SBDF · 2686063
  • Tralokinumab-ldrm Auto-Injector [Adbry] SBDFP · 2686064
  • Adbry Injectable Product SBDG · 2589382
  • Adbry BN · 2589380

📦 FDA Products & Package NDCs

2 products · 6 package NDCs
6 package NDCs map to RxCUI 2686061 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50222-0346-02 2 SYRINGE, GLASS in 1 CARTON (50222-346-02) / 1 mL in 1 SYR... Adbry LEO Pharma Inc. 2022-01-02
50222-0346-04 2 CARTON in 1 CARTON (50222-346-04) / 2 SYRINGE, GLASS in 1... Adbry LEO Pharma Inc. 2022-01-02
50222-0346-92 2 SYRINGE, GLASS in 1 CARTON (50222-346-92) / 1 mL in 1 SYR... Adbry LEO Pharma Inc. 2022-01-02
50222-0350-01 1 SYRINGE, GLASS in 1 CARTON (50222-350-01) / 2 mL in 1 SYR... Adbry LEO Pharma Inc. 2024-07-01
50222-0350-02 2 SYRINGE, GLASS in 1 CARTON (50222-350-02) / 2 mL in 1 SYR... Adbry LEO Pharma Inc. 2024-07-01
50222-0350-91 1 SYRINGE, GLASS in 1 CARTON (50222-350-91) / 2 mL in 1 SYR... Adbry LEO Pharma Inc. 2024-07-01
Observed labelers: LEO Pharma Inc. (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.